GRAIL, Inc. (GRAL) AI Stock Analysis

GRAIL, Inc. is a Menlo Park, California-based biotechnology firm focused on advancing technologies for early cancer detection. Founded in 2015 as PSC15, Inc. and rebranded in January 2016, the company develops screening and diagnostic solutions to identify cancer at its earliest stages. Its key product is Galleri, a screening test for asymptomatic individuals aged 50 and older designed to detect multiple cancer types early. GRAIL also develops the Diagnostic Aid for Cancer (DAC) to accelerate resolutions for patients with suspected cancer, as well as tests for minimal residual disease and post-diagnostic applications. It operates as a subsidiary of Illumina, Inc., utilizing strategic collaborations and genetic sequencing technology.

Annual revenue grew from $14.6M in FY2021 to $147.2M in FY2025, representing a 4-year CAGR of 78.1%. Annual growth slowed from 280.2% in FY2022 to 67.6% in FY2023, 34.9% in FY2024, and 17.2% in FY2025. Gross margin improved from -684.4% in FY2021 to -42.5% in FY2025, while operating margin improved from -8659.6% to -363.0%. Net losses narrowed from -$5.40B in FY2022 to -$408.4M in FY2025, yielding an EPS of -$11.18. In the latest quarter ended June 30, 2026, revenue increased 25.7% year-over-year, bringing trailing twelve-month revenue to $165.3M with an operating margin of -332.0% and an EPS of -$9.70.

As of June 30, 2026, GRAIL held $861.6M in cash and short-term investments and $91.3M in total debt, resulting in net cash of $770.3M. The company's current ratio stood at 10.95 and its debt-to-equity ratio was 0.04 against $2.54B in shareholders' equity. Operating cash flow for FY2025 was -$299.0M, matching free cash flow of -$299.0M after capital expenditures of $909,000. In FY2025, research and development expenses were $195.8M, down from $322.4M in FY2024.

At a last close of $117.81 on October 16, 2026, GRAIL had a market capitalization of $5.26B and an enterprise value of $4.08B. The stock trades at a price-to-sales multiple of 31.8x and an enterprise value-to-revenue multiple of 24.7x, compared to a median price-to-sales of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 1.9x. Over the past year, GRAIL shares returned 36.3%, outperforming the S&P 500 (SPY) return of 16.8%, and traded 54.9% above their 200-day average with a beta of 2.84.

Among Wall Street analysts covering GRAIL, there are 5 Strong Buy and 6 Hold ratings, with no Buy, Sell, or Strong Sell ratings. The mean price target is $131.30, representing an upside of 11.5% from the last close of $117.81. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $180.9M and an EPS of -$7.52. For the next fiscal year, 4 analysts estimate revenue of $226.9M and an EPS of -$8.25. The company beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of GRAIL, Inc. (GRAL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GRAL income statement, GRAL balance sheet, GRAL key metrics, GRAL analyst forecast, GRAL chart. See the GRAL stock overview for the latest quote and news.